Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5265282 | 0.89 | BCHE (0.31) | BCHEACHEPIN1HIF1ASIRT1 | |
| SCHEMBL5267902 | 0.89 | SIRT1 (0.33) | BCHEACHEPIN1HIF1ASIRT1 | |
| SCHEMBL5265083 | 0.85 | — | — | |
| SCHEMBL6078534 | 0.85 | — | — | |
| SCHEMBL5510354 | 0.79 | MAOB (0.35) | ACHEHIF1ASIRT1 | |
| SCHEMBL14686069 | 0.79 | MAOB (0.36) | HIF1ASIRT1 | |
| SCHEMBL5265504 | 0.79 | SIRT1 (0.33) | BCHEACHEPIN1HIF1ASIRT1 | |
| SCHEMBL6079529 | 0.79 | SIRT1 (0.33) | PIN1HIF1ASIRT1 | |
| SCHEMBL5361266 | 0.77 | — | — | |
| SCHEMBL5440151 | 0.73 | SIRT1 (0.33) | SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1317437-B1 | SYNTHESIS OF 4-ALPHA-ARYLEPICATECHINS | MARS INC (US) | 2007-10-03 | — | — | EP | claimed |
| US-7126014-B2 | Synthesis of epecatechin-4α, 8-epicatechin and -catechin dimers and derivatives thereof | MARS, INC. | 2006-10-24 | — | — | US | claimed |
| US-6476241-B1 | Synthesis of 4α-arylepicatechins | MARS INCORPORATED | 2002-11-05 | — | — | US | claimed |
| EP-1317437-B1 | SYNTHESIS OF 4-ALPHA-ARYLEPICATECHINS | MARS INC (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20070197804-A1 | Synthesis of 4alpha-arylepicatechins | MARS, INCORPORATED | 2007-08-23 | — | — | US | disclosed |
| US-7126014-B2 | Synthesis of epecatechin-4α, 8-epicatechin and -catechin dimers and derivatives thereof | MARS, INC. | 2006-10-24 | — | — | US | disclosed |
| US-20050014958-A1 | Synthesis of 4alpha-arylepicatechins | MARS, INCORPORATED | 2005-01-20 | — | — | US | disclosed |
| US-6720432-B2 | OXIDIZING HYDROXYL-PROTECTED BENZYLEPITCATECHIN, ADDING NUCLEOPHILIC ARYL-ORGANOMETALLIC REAGENT, AND DEOXYGENATING FORMING COMPOUNDS SUCH AS 3,5,7,3',4'-PENTA-O-BENZYL-4-HYDROXYEPICATECHIN; PROCYANIDINS | MARS INCORPORATED | 2004-04-13 | — | — | US | disclosed |
| US-20030100775-A1 | Synthesis of 4alpha-arylepicatechins | MARS INCORPORATED | 2003-05-29 | — | — | US | disclosed |
| US-6476241-B1 | Synthesis of 4α-arylepicatechins | MARS INCORPORATED | 2002-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100775-A1 | Synthesis of 4alpha-arylepicatechins | FABP4, TEAD4, FABP7 | BCHE 1134/4885ACHE 3773/4885PIN1 3735/4885 |
| US-20050014958-A1 | Synthesis of 4alpha-arylepicatechins | FABP7, FABP4, TEAD4 | BCHE 724/4885ACHE 3555/4885PIN1 4127/4885 |
| US-20070197804-A1 | Synthesis of 4alpha-arylepicatechins | FABP7, FABP4, TEAD4 | BCHE 724/4885ACHE 3555/4885PIN1 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.